PDS Biotechnology Corporation (PDSB) revealed pretty balanced Earnings results as it emphasizes cost-cutting measures

Share on facebook
Share on twitter
Share on linkedin
Share on whatsapp

Thursday, November 12, 2020, A company in the biotech sector PDS Biotechnology Corporation (Nasdaq: PDSB), publicized its quarterly results for the period ended 30 September 2020 and provided a business update.

Net losses were almost $3.9 million for the third quarter of 2020, or $0.23 per basic share and diluted share, compared to a net loss of approximately $5.8 million for the third quarter of 2019, or $1.10 per basic share and diluted share.


The 2021 Backdoor Crypto Portfolio (free)

Even if you’re not actively in crypto, you deserve to know what’s actually going on...

Because while leading assets such as Bitcoin (BTC) and Ethereum (ETH) are climbing in value, a select group of public “crypto stocks” are surging right along with them. More importantly, these stocks are outpacing the returns these leading crypto assets aren already producing.

Click here to get the full story… along with our long list of backdoor Bitcoin strategies. It’s free.

Sponsored



For the previous quarter, R&D costs reached about $2.1 million, in contrast to $1.8 million at the same time in 2019, an improvement of 12 percent. The rise was mainly due to an increase in tech addition to operations of $0.1 million and clinical trials of $0.3 million, counterbalanced by a decline in professional fees of $0.1 million and regulatory expenses of $0.1 million.

General and administrative expenses were roughly $1.8 million for the period compared to $3.0 million years over year, which was a decline of 40 percent. The drop was largely due to a $0.2 million cut down in salaries and benefits, $0.1 million in expenditures for services and offices, $0.3 million in insurance costs, $0.6 million in professional fees, and $0.1 million in legal fees, offset by a rise in permits, taxes, and fees of $0.1 million.

Expenses related to the operation were almost $3.9 million for the third quarter, in comparison with total operating expenses of $5.8 million during the same quarter year before, which was a 33 percent decline.

The clinical-stage immunotherapy company that develops novel cancer therapies and medications for transferrable diseases based on the company’s patented activating technology Versamune T-cell. Its cash balance was recorded $33.5 million as of September 30, 2020.

PDS Biotechnology Corporation (Nasdaq: PDSB) shares were trading 1.94% away from the 20-day Simple Moving Average. Its last month’s performance was recorded -9.73% in contrast with the 6 months performance of 151.38%.

Sign up for our FREE Newsletter and get:

Leave a Comment

Your email address will not be published. Required fields are marked *

Sign up for our FREE Newsletter and get:

Get The Best Stocks To Trade Every Day!

Join now to get the NewsHeater.com pre-market morning brief 100% free

We do not sell or share your information with anyone.

Get Best Morning Financial Newsletter... 100% Free

Best stocks ideas

Analysts’ Upgrades & Downgrades

Important Earnings

Insider Watchlist

We do not sell or share your information with anyone.

Get The Best Stocks To Trade Every Day!...100% Free

We do not sell or share your information with anyone.